Mylan Completes Acquisition of Generics Business of Merck KGaA

Pittsburgh (ots/PRNewswire) -

Mylan (NYSE: MYL) announced today that it has completed its
acquisition of Merck KGaA's generics business ("Merck Generics") to
become one of the largest quality generics and specialty
pharmaceuticals companies in the world. Mylan and Merck KGaA
initially announced the signing of a definitive agreement under which
Mylan would acquire Merck Generics for EUR 4.9 billion (US$6.8
billion) in an all-cash transaction on May 12, 2007.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer
said, "The new Mylan now has all of the critical attributes we need
to ensure future success and deliver powerful growth. We have
enhanced scale and stability, a truly global reach, vertical and
horizontal integration, and breadth and depth in our management team.
Most importantly, we have a common purpose and dedication to
executing on our strategy and delivering superior shareholder
returns."

The new Mylan is the third largest generic company worldwide,
employs more than 11,000 people and has a global presence in more
than 90 countries. Mylan's broad product offering now includes more
than 570 products and the world's second largest portfolio of active
pharmaceutical ingredients (APIs) with 126 U.S. drug master files
(DMFs). Mylan has a powerful global pipeline with more than 255
applications or dossiers pending regulatory approval. The new Mylan
will benefit from substantial operational efficiencies and economies
of scale from increased sales volumes and its vertically and
horizontally integrated platform. Dey, Mylan's specialty
pharmaceuticals business, brings additional exciting and diversified
opportunities through its existing strengths in the respiratory
arena.

Mr. Coury continued, "The scale of the new Mylan is evident in
every area of our business: we have scale in our geographic reach,
scale in R&D, scale in manufacturing, scale in API, scale in our
combined product portfolio, and scale in our global commercial
footprint. We will leverage this scale to drive operational
efficiencies and extract synergies from our combined company, while
attracting exciting new opportunities. We have also created an
extremely well-balanced and diversified company, with significantly
reduced risks related to any one particular market or product.
Importantly, we will also ensure that we retain the qualities that
customers around the world have come to expect from both Mylan and
Merck Generics.

"The Merck Generics business is even stronger than we expected
and, through the integration planning, we have confirmed that we
truly share a common culture and values centered on quality,
integrity, reliability and service. I am thrilled to welcome Merck
Generics nearly 5,000 employees to the new and expanded Mylan family.
After months of careful preparation, we have hit the ground running
with the integration of our businesses and I am delighted that we
will be operating as a single, integrated company from day one."

Mylan also announced today that the company will change its name
from Mylan Laboratories Inc. to Mylan Inc. to better reflect the
broader scope of its business. The Company also confirmed that it has
changed its financial year to begin reporting on a calendar year
basis.

Investor Day on October 3

Mylan will provide more details on its go-forward strategy and its
financial outlook during its Investor Day in New York, New York, on
October 3, 2007. The agenda will include presentations delivered by
each of Mylan's global regional heads and several members of Mylan's
senior management team. The presentations will be available live via
webcast beginning at 8:30 a.m. ET.

To access the live webcast, go to Mylan's Web site at
www.mylan.com and click on the webcast icon at least 15 minutes
before the event is scheduled to begin to register and download or
install any necessary audio software. A replay of the webcast will be
available on www.mylan.com until November 2, 2007.

About Mylan

Mylan Inc. is one of the world's leading quality generic and
specialty pharmaceutical companies. The Company offers one of the
industry's broadest and highest quality product portfolios, a robust
product pipeline and a global commercial footprint through operations
in more than 90 countries. Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the largest
active pharmaceutical ingredient (API) manufacturers in the world.
Dey L.P., Mylan's fully integrated specialty business, provides the
Company with innovative and diversified opportunities in the
respiratory and allergy therapeutic areas.

For more information about Mylan, please visit www.mylan.com.

Forward-Looking Statements

This press release contains statements that constitute
"forward-looking statements", including with regard to Mylan's future
success, the anticipated benefits of operational efficiencies and
leverage, and expected product and other opportunities. These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Because such
statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to: challenges and
costs relating to integration of the two businesses; the effect of
any changes in customer and supplier relationships and customer
purchasing patterns; the impact and effects of legal or regulatory
proceedings, actions or changes; general market perception of the
transaction; the ability to attract and retain key personnel; changes
in economic and financial conditions of the Company's business;
uncertainties and matters beyond the control of management; and the
other risks detailed in the Form 10-Q for the quarter ended June 30,
2007 and the other periodic reports filed by the Company with the
Securities and Exchange Commission. The Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release.

Web site: http://www.mylan.com

ots Originaltext: Mylan Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Kris King, Mylan Inc., +1-724-514-1800; Nina Devlin or Cindy
Leggett-Flynn, Brunswick Group, +1-212-333-3810, for Mylan Inc.